We might get a more definitive answer to this now that GSK might be incentivized to bear the cost of a large trial. The upside to their Shingrix franchise would be very significant if positive.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.